Fulgent Genetics (NASDAQ:FLGT) & PPJ Enterprise (OTCMKTS:PPJE) Head to Head Survey

PPJ Enterprise (OTCMKTS:PPJE) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Earnings & Valuation

This table compares PPJ Enterprise and Fulgent Genetics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PPJ Enterprise	$670,000.00	1.33	$10,000.00	N/A	N/A
Fulgent Genetics	$283.47 million	2.56	-$42.71 million	($1.39)	-16.86

PPJ Enterprise has higher earnings, but lower revenue than Fulgent Genetics.

Analyst Recommendations

This is a summary of current ratings and target prices for PPJ Enterprise and Fulgent Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PPJ Enterprise	0	0	0	0	0.00
Fulgent Genetics	1	1	2	1	2.60

Fulgent Genetics has a consensus target price of $32.00, suggesting a potential upside of 36.52%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than PPJ Enterprise.

Institutional & Insider Ownership

48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PPJ Enterprise and Fulgent Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PPJ Enterprise	N/A	N/A	N/A
Fulgent Genetics	-13.62%	-2.55%	-2.36%

Risk and Volatility

PPJ Enterprise has a beta of -0.35, suggesting that its share price is 135% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Summary

Fulgent Genetics beats PPJ Enterprise on 9 of the 13 factors compared between the two stocks.

About PPJ Enterprise

PPJ Healthcare Enterprises, Inc., through its subsidiaries, provides automated healthcare reimbursement cycle, online health information digital-systems, and practice information management digital-system software to health care providers and general businesses worldwide. The company offers the Automated Biller, a medical billing system that allows physicians to bill their medical insurance claims at the point of service without data entry, coding, or billing personnel. It also provides billing, specialty medical billing, collection, and workers comp lien collection services for health care providers in the areas of pain management, anesthesia and surgery centers practices, and various specialties of medicine. The company was formerly known as PPJ Enterprise and changed its name to PPJ Healthcare Enterprises, Inc. in October 2014. PPJ Healthcare Enterprises, Inc. was founded in 2000 and is headquartered in Reno, Nevada.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.